Vinay Kumar Katakam 
,
Sunil Reddy,
Pavan Kumar Panakanti,
Madhusudan Rao Yamsani
For correspondence:- Vinay Katakam Email: yamsani123@gmail.com Tel:+918702570543
Received: 6 March 2013 Accepted: 4 February 2014 Published: 23 April 2014
Citation: Katakam VK, Reddy S, Panakanti PK, Yamsani MR. Design and Evaluation of a Novel Gas Formation-Based Multiple-Unit Gastro-Retentive Floating Drug Delivery System for Quetiapine Fumarate. Trop J Pharm Res 2014; 13(4):489-496 doi: 10.4314/tjpr.v13i4.1
© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To develop a gastro-retentive formulation of quetiapine fumarate in the form of floating mini-tablets.
Methods: The system consisted of core units prepared by direct compression process, which were coated with three successive layers, namely, an inner seal coat, effervescent layer and an outer polymeric layer of polymethacrylates.
Results: Mini-tablets coated with Eudragit RS 30D (5, 7.5 and 10%) released ≤ 85% of the drug after 12 h, while those coated with Eudragit RL 30D (5, 7.5 and 10%) released ≥ 85% drug within the same period. Drug release kinetic studies showed that drug diffusion fitted best to zero order and Higuchi models, indicating that drug release was anomalous non-Fickian transport. In vivo gastric residence time results indicate that the units remained in the stomach for about 6 h (n = 3). There was no significant change in dissolution profiles before and after storage at 40°C and 75% RH for 6 months.
Conclusion: The developed floating mini-tablets of quetiapine fumarate exhibit prolonged release for ≥12 h, and thus may improve bioavailability and minimize fluctuations in plasma drug concentrations.
Fulltext in PDF